We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1) (OPUS-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01421498
Recruitment Status : Completed
First Posted : August 22, 2011
Results First Posted : February 24, 2017
Last Update Posted : June 11, 2021
Information provided by (Responsible Party):
Takeda ( Shire )

Brief Summary:
The purpose of the study is to evaluate the efficacy of SAR 1118 Ophthalmic Solution (5.0%) compared to placebo in the treatment of Dry Eye. The safety and tolerability of SAR 1118 Ophthalmic Solution (5.0%) compared to placebo in subjects with dry eye when administered BID for 12 weeks will also be evaluated.

Condition or disease Intervention/treatment Phase
Keratoconjunctivitis Sicca Dry Eye Disease Drug: Lifitegrast Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 588 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Randomized, Double- Masked and Placebo-Controlled Study Evaluating the Efficacy of a 5.0% Concentration of SAR 1118 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (OPUS-1)
Actual Study Start Date : August 29, 2011
Actual Primary Completion Date : April 28, 2012
Actual Study Completion Date : April 28, 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Lifitegrast

Arm Intervention/treatment
Experimental: 5.0% Lifitegrast
Drug: Lifitegrast
Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: 12 weeks
Other Name: SAR 1118

Placebo Comparator: Placebo
Drug: Placebo
Dosage Form: Ophthalmic Solution Frequency: BID Duration: 12 weeks

Primary Outcome Measures :
  1. Ocular Sign: Change From Baseline in Inferior Corneal Fluorescein Staining to Day 84 [ Time Frame: Baseline (Day 0) to Day 84 ]
    Corneal staining was performed to grade the degree of corneal epithelial cell injury as measured by fluorescence using slit-lamp examination. The staining was graded with the Ophthalmic Research Associates, Inc. (ORA) scale. The corneal surface is divided into three regions: superior, central and inferior. The scores for each of these 3 regions ranged from 0 to 4 (0=no staining/none; 1=occasional/trace; 2=countable/mild; 3=uncountable, but not confluent/moderate; 4=confluent/severe) with 0.5 point increments, and lower score indicates a better outcome. Inferior corneal fluorescein staining scores from the study eye only were reported. Study eye is the 'worse eye', defined as the eye with worse (higher) score at baseline.

  2. Ocular Symptom: Change From Baseline in Visual-Related Subscale of the Symptom Functional Scale Score to Day 84 [ Time Frame: Baseline (Day 0) to Day 84 ]
    The symptom functional scale is a validated instrument for ocular surface diseases, measuring the ocular symptoms, vision-related function, and environmental triggers. The 12 items of the symptom functional scale questionnaire were graded on a scale of 0 (none of the time) to 4 (all of the time). The index consisted of 3 sub scales: symptoms (sensitivity to light, gritty sensation, pain, blurred vision, and poor vision [Items 1-5]), visual-related sub scale of the symptom functional scale (ability to read, drive at night, use a computer, watch television [Items 6-9]), and environmental triggers (windy conditions, low humidity, air conditioning [Items 10-12]). The symptom functional scale was scored on a scale of 0 to 100, with higher scores representing greater disability. Negative change from baseline indicates improvement.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Willing and able to read, sign, and date the informed consent and HIPAA documents
  • Willing and able to comply with all study procedures
  • Be at least 18 years of age
  • Patient-reported history of dry eye in both eyes
  • Demonstrate a positive response when exposed to the Controlled Adverse Environment model
  • A negative urine pregnancy test if female of childbearing potential and must use adequate birth control throughout the study period

Exclusion Criteria:

  • Any ocular condition that, in the opinion of the Investigator, could affect study parameters including, but not limited to, active ocular infection, ocular inflammation, glaucoma, and/or diabetic retinopathy
  • Unwilling to avoid wearing contact lenses for 7 days prior to and for duration of the study period
  • Any blood donation or significant loss of blood within 56 days of Visit 1
  • Any history of immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.
  • Use of any topical ophthalmic preparations (including artificial tear substitutes) 72 hrs prior to Visit 1 and during the study
  • Any significant chronic illness that could interfere with study parameters
  • History of laser-assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical procedure within 12 months prior to Visit 1; or any scheduled ocular surgical procedure during the study period.
  • Known history of alcohol and/or drug abuse
  • Subjects with Dry eye secondary to scarring or destruction of conjunctival goblet cells (as with Vitamin A deficiency)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01421498

Layout table for location information
United States, Connecticut
OPUS-1 Investigational Site
Waterbury, Connecticut, United States, 06708
United States, Kentucky
OPUS-1 Investigational Site
Louisville, Kentucky, United States, 40405
United States, Maine
OPUS-1 Investigational Site
Augusta, Maine, United States, 04330
OPUS-1 Investigational Site
Lewiston, Maine, United States, 04243
United States, Massachusetts
OPUS-1 Investigational Site
Andover, Massachusetts, United States, 01840
OPUS-1 Investigational Site
Lancaster, Massachusetts, United States, 01523
OPUS-1 Investigational Site
Quincy, Massachusetts, United States, 02169
OPUS-1 Investigational Site
Wakefield, Massachusetts, United States, 01880
OPUS-1 Investigational Site
Winchester, Massachusetts, United States, 01890
United States, New Hampshire
OPUS-1 Investigational Site
Derry, New Hampshire, United States, 03038
OPUS-1 Investigational Site
Manchester, New Hampshire, United States, 03101
United States, Tennessee
OPUS-1 Investigational Site
Memphis, Tennessee, United States, 38119
United States, Virginia
OPUS-1 Investigational Site
Norfolk, Virginia, United States, 23502
Sponsors and Collaborators
Layout table for investigator information
Study Director: Study Director Takeda
Publications of Results:
Layout table for additonal information
Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT01421498    
Other Study ID Numbers: 1118-KCS-200
First Posted: August 22, 2011    Key Record Dates
Results First Posted: February 24, 2017
Last Update Posted: June 11, 2021
Last Verified: June 2021
Keywords provided by Takeda ( Shire ):
ophthalmic delivery
Dry Eye
Additional relevant MeSH terms:
Layout table for MeSH terms
Dry Eye Syndromes
Keratoconjunctivitis Sicca
Eye Diseases
Lacrimal Apparatus Diseases
Conjunctival Diseases
Corneal Diseases
Ophthalmic Solutions
Pharmaceutical Solutions